Supriya Lifescience ramps up capacity and global readiness for next phase of growth

Recently, Supriya Lifescience expanded its manufacturing capacity at the Lote facility with the commissioning of Module E, which has enhanced operational efficiency and increased capacity utilisation from 70 per cent in FY2025 to 78 per cent in the first half of FY 2026.

- 

The company is also planning to commence commercial operations of its Ambernath formulation facility in the second half of FY 2026. Dr Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience highlights how new facility expansions, stronger regulatory capabilities, and rising capacity utilisation are positioning the company to deepen its global footprint and drive sustained growth across key therapeutic segments, in an exclusive interview with Swati Rana

Supriya Lifescience has built a strong global presence in Active Pharmaceutical Ingredients. What has guided this journey?

Our growth has been guided by a clear focus on niche Active Pharmaceutical Ingredients, strong backward integration and a commitment to regulatory excellence. Over the years, we have expanded into more than 128 countries, and exports today contribute between 81 per cent and 84 per cent of our revenue. Our facilities hold approvals from major regulatory agencies such as the United States Food and Drug Administration, the European Directorate for the Quality of Medicines, the World Health Organisation, the Pharmaceuticals and Medical Devices Agency, the Korea Food and Drug Administration and ANVISA. This regulatory strength, combined with consistent quality and reliable supply, has helped us build a trusted global presence.

What have been the most decisive milestones shaping Supriya’s current position?